Evidence map›Paper›PMID 34562262›Full record

Trial reportInfection2022

Adjunctive interleukin-2 for the treatment of drug-susceptible tuberculosis: a randomized control trial in China.

Wenjuan Nie, Jun Wang, Jianfeng Zeng, Qingfeng Wang, Yadong Du, Qi Tan, Weiping Xie, Qunyi Deng, Guofang Deng, Xiujie Li and 21 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 14 institutions in 1 country.

Wenjuan Nie *Tuberculosis Department, Beijing Chest Hospital Affiliated to Capital Medical University, No 9, Beiguan street, Tongzhou District, Beijing, 101149, People's Republic of China.
Jun Wang *Tuberculosis Department, Beijing Chest Hospital Affiliated to Capital Medical University, No 9, Beiguan street, Tongzhou District, Beijing, 101149, People's Republic of China.
Jianfeng Zeng *Shenzhen Third People's Hospital, Shenzhen, China.
Qingfeng WangTuberculosis Department, Beijing Chest Hospital Affiliated to Capital Medical University, No 9, Beiguan street, Tongzhou District, Beijing, 101149, People's Republic of China.
Yadong DuTuberculosis Department, Beijing Chest Hospital Affiliated to Capital Medical University, No 9, Beiguan street, Tongzhou District, Beijing, 101149, People's Republic of China.
Qi TanJiangsu Provincial People's Hospital, Nanjing, China.
Weiping XieJiangsu Provincial People's Hospital, Nanjing, China.
Qunyi DengShenzhen Third People's Hospital, Shenzhen, China.
Guofang DengShenzhen Third People's Hospital, Shenzhen, China.
Xiujie LiJiamusi Tuberculosis Control Hospital, Jiamusi, China.
Zhihui LiHebei Chest Hospital, Shijiazhuang, China.
Jie ZhaoHebei Chest Hospital, Shijiazhuang, China.
Jianjian PangXi'an Chest Hospital, Xi'an, China.
Kun LuanMudanjiang Infectious Disease Hospital, Mudanjiang, China.
Lixiang ChuMudanjiang Infectious Disease Hospital, Mudanjiang, China.
Huiping DuanTaiyuan Fourth People's Hospital, Taiyuan, China.
Chunyan ZhangHandan Infectious Disease Hospital, Handan, China.
Qing JiDalian Tuberculosis Hospital, Dalian, China.
Xiaohong ChenFuzhou Pulmonary Hospital, Fuzhou, China.
Jing ChenGuizhou Public Health Treatment Center, Anshun, China.
Nian WangGuizhou Public Health Treatment Center, Anshun, China.
Yu ChenZhengzhou Sixth People's Hospital, Zhengzhou, China.
Chao QiuJiamusi Cancer and Tuberculosis Hospital, Jiamusi, China.
Aihua DengJiangxi Chest Hospital, Nanchang, China.
Pengfei RenZhengzhou Sixth People's Hospital, Zhengzhou, China.
Yufeng LiuQingdao Chest Hospital, Qingdao, China.
Chunxiang LiChangsha Central Hospital, Changsha, China.
Shipeng CaoChangsha Central Hospital, Changsha, China.
Haiqing LiuFuyang No.2 Hospital, Fuyang, China.
Hao YanFuyang No.2 Hospital, Fuyang, China.
Naihui ChuTuberculosis Department, Beijing Chest Hospital Affiliated to Capital Medical University, No 9, Beiguan street, Tongzhou District, Beijing, 101149, People's Republic of China. chunaihui1994@sina.com.ORCID http://orcid.org/0000-0003-1109-1983
Capital Medical University · CNShenzhen Third People’s Hospital · CNChangsha Central Hospital · CNFuyang Maternity and Child Health Care Hospital · CNHospital of Hebei Province · CNJiamusi University · CNMudanjiang Medical University · CNThe Sixth People's Hospital of Zhengzhou · CNFourth People's Hospital of Taiyuan · CNFuzhou Pulmonary Hospital of Fujian · CNHandan College · CNJiangxi Chest Hospital · CNQingdao University · CNXi'an Chest Hospital · CN

Funding

national major science and technology projects of china 2015ZX10003001-002national major science and technology projects of china 2017ZX09304009
6 · The paper itself

Abstract

purposeEvaluation of the efficacy and safety of IL-2 in the treatment of drug-susceptible tuberculosis.

methodsFirst, the cases of diagnosed drug-susceptible tuberculosis were randomized into two groups-the control group that received the background regimen of isoniazid, rifampin, pyrazinamide, and ethambutol, and the experimental group that received the background regimen plus IL-2. The efficacy and safety evaluations were performed throughout the therapy process as well as 12 months after the treatment completion.

resultsA total of 1151 patients underwent the randomization, among which 539 (96.2%) of the 560 in the experimental group achieved the sputum culture conversion to negative, compared to the 551 (93.2%) of the 591 in the control group, after 2 months of treatment, with significant difference observed between the groups (P = 0.025). Cavity closure after 2 months in the IL-2 (experimental) group was 60/211 (28.4%) compared to 46/248 (18.5%) in the control group, with a significant difference between the groups (P = 0.001). After treatment completion, the proportion of favorable outcomes was 559/560 (99.8%) in the experimental group and 587/591 (99.3%) in the control group, with no significant difference between the groups. Twelve months after treatment completion, relapse occurred in 15/560 (2.6%) in the IL-2 group and 19/591 (3.2%) in the control group, with no significant difference.

conclusionIL-2 may enhance culture conversion and the cavity closure rate in the early treatment phase, although the enhancement may not be significant after treatment completion.

Indexed as

TuberculosisTuberculosis, PulmonaryAntitubercular AgentsDrug Therapy, CombinationHumansInterleukin-2Treatment OutcomeAntitubercular AgentsInterleukin-2Drug-susceptibleInterleukin-2Randomized control trialTuberculosis

Identifiers

PMID34562262
OpenAlexW3201024268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.